People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...

The conference also served to educate the attendees about UAMS' Odyssey Clinic. Dr. Craig Jones, the clinic's program manager, said it opened July 1 and works with schizophrenia patients 16 years or ...

Despite schizophrenia, the jury rejected the defense's contention that the man was insane at the time of the 2021 attack.

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

Dr. James Lawler, of the University of Nebraska’s Global Center for Health Security, on trying to pick out the bird flu virus from among myriad other viruses present during the time of year when ...

Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors.

California Gov. Gavin Newsom on Friday signed a package of legislation meant to strengthen mental health and substance abuse ...

The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...

CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy ...

Bristol Myers Squibb has received U.S. FDA approval for a new schizophrenia drug, marking the first new antipsychotic medication in decades. The drug, Cobenfy, lacks warnings about increased mortality ...

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...